Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS).
Back to dashboard
Company Information
About this company
Key people
Michael Thomas Heffernan
Independent Chairman of the Board
Gilla Kaplan
Independent Director
Kevin R. Lind
Independent Director
Garry A. Neil
President, Chief Executive Officer, Director
Christopher Sullivan
Chief Financial Officer
Taylor Boyd
Chief Business Officer
Mittie Doyle
Chief Medical Officer
Jennifer Riley
Chief Strategy Officer
Paul C. Varki
Chief Legal Officer
Rita I. Jain
Independent Director
Aaron Kantoff
Independent Director
Click to see more
Key facts
- Shares in issue53.63m
- EPICAVTX
- ISINUS05338F3064
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$1.06bn
- Employees33
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.